Phase 2 Data: CAD-1005 Cuts Thrombotic Events by >25% in HIT
CVKD sits 21% above its 52-week low of $2.55.
Summary
Cadrenal's first-in-class 12-LOX inhibitor CAD-1005 showed a greater than 25% reduction in new or worsening thrombotic events in a Phase 2 HIT trial, presented as a late-breaker at ISTH 2026. The data, while not powered for significance, demonstrated a clear efficacy signal with no serious adverse events or major bleeding. This is the first randomized, placebo-controlled trial in HIT and provides critical framework for the upcoming pivotal Phase 3. The news follows a recent $8.8M private placement and an End-of-Phase 2 FDA meeting that cleared the path to Phase 3. With a cash runway only into October 2026, positive data strengthens partnering and financing prospects. The stock, at a $8.3M market cap, is highly sensitive to clinical progress.
At the time of this announcement, CVKD was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $2.55 to $14.64. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.